小麦纤维素联合乳果糖治疗儿童 功能性便秘的临床观察

Application of Fiberform and Lactulose in treatment of functional constipation in children

摘要:

目的 探讨小麦纤维素颗粒联合乳果糖治疗婴幼儿功能性便秘（FC）的临床疗效和安全性。方法 将107 例FC 患儿随机分为实验组56 例和对照组51 例。所有患儿均给予相同的基础治疗，试验组使用小麦纤维 素颗粒加乳果糖治疗；对照组只使用乳果糖，疗程14 d，维持基础治疗≥２周。比较两组便秘症状评分、不良反 应差异。结果 两组在治疗2 周排便困难对照组、排便次数；对照组的评分均较治疗前下降，差异有统计学意义 （P <0.05）。试验组治疗4 周与治疗2 周评分比较，差异有统计学意义（P <0.05），而对照组治疗4 周与治疗2 周 评分比较，差异无统计学意义（P >0.05）。治疗期间两组不良反应发生率比较差异无统计学意义（P >0.05）。结论 小麦纤维素颗粒联合乳果糖治疗可有效恢复患儿的正常排便生理，缓解便秘症状，且安全性好，在服药期间和停 药后2 周可获得满意的疗效。

Abstract:

Objective To investigate efficacy and safety of Fiberform and Lactulose for the treatment of functional constipation in children. Methods This retrospective study enrolled 107 children aging from 0 to 4 years old. All children including the ones in control group received standard treatment including Lactulose. Patients in observation group received additional Fiberform. Primary efficacy was evaluated by stool difficulty and stool frequency score. Secondary endpoint of this study was to record adverse reactions. Results The score of stool difficulty and stool frequency was comparable in the two groups before any treatments (P > 0.05). Score of stool difficulty and stool frequency were improved significantly in both group after standard treatments compared with those prior any treatments (P < 0.05). Score of stool difficulty and stool frequency were significantly decreased after 2 and 4 weeks of treatment in observation group when compared with those in control group (P < 0.05). The incidence of adverse events was similar in both groups (P > 0.05). Conclusions Fiberform and Lactulose exert superior efficacy to the treatment of functional constipation in children without obvious or severe side effects.